Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

BACKGROUND: In patients with stage III melanoma, despite surgical resection and adjuvant systemic therapy, locoregional recurrences still occur. The randomized, phase III Trans-Tasman Radiation Oncology Group (TROG) 02.01 trial demonstrated that adjuvant radiotherapy (RT) after complete lymphadenect...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhave, Prachi, Hong, Angela, Lo, Serigne N, Johnson, Rebecca, Mangana, Johanna, Johnson, Douglas B, Dulgar, Ozgecan, Eroglu, Zeynep, Yeoh, Hui-Ling, Haydon, Andrew, Lodde, Georg C, Livingstone, Elisabeth, Khattak, Adnan, Kähler, Katharina, Hausschild, Axel, McArthur, Grant A, Menzies, Alexander Maxwell, Long, Georgina, Wang, Wei, Carlino, Matteo S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008434/
https://www.ncbi.nlm.nih.gov/pubmed/36889810
http://dx.doi.org/10.1136/jitc-2022-006629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008434/
https://www.ncbi.nlm.nih.gov/pubmed/36889810
http://dx.doi.org/10.1136/jitc-2022-006629

Ejemplares similares